Volčanšek Špela, Lunder Mojca, Janež Andrej
Clinical Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre Ljubljana, Zaloška 7, 1000 Ljubljana, Slovenia.
Medical Faculty, University of Ljubljana, Vrazov trg 2, 1000 Ljubljana, Slovenia.
Healthcare (Basel). 2023 Jul 28;11(15):2154. doi: 10.3390/healthcare11152154.
Type 1 (T1D) and type 2 diabetes (T2D) are determinants of health-related outcomes including health-related quality of life (HRQOL). We aimed to determine differences in HRQOL between older adults with T1D and T2D and specific factors influencing HRQOL in this age group. This study used a cross-sectional design with 56 age- and HbA1c-matched T1D and T2D patients (aged 68.9 ± 7.8 years; 55% had T2D). We employed several validated questionnaires (Short Form-36 (SF-36) and the EuroQol-5 Dimensions/Visual Analog Scale (VAS)) to investigate the relationships between HRQOL domains and diabetes type, glycemic control, complications, and comorbidities. T1D was associated with better self-reported general health (assessed with the SF-36 general health domain ( = 0.048) and the EuroQol-5 VAS ( = 0.002), whereas no significant differences in the other SF-36 domains, self-reported diabetes distress, anxiety, or depression were found. Most HRQOL domains were not associated with HbA1c or the presence of diabetes complications. The most significant reduction in HRQOL was experienced by patients with higher BMIs, irrespective of the diabetes type. The obtained HRQOL data could be used in clinical settings for evidence-based patient education focused on specific subgroups of patients, as well as in national healthcare policies, e.g., interventions designed to alleviate obesity.
1型糖尿病（T1D）和2型糖尿病（T2D）是包括健康相关生活质量（HRQOL）在内的健康相关结局的决定因素。我们旨在确定老年T1D和T2D患者在HRQOL方面的差异以及影响该年龄组HRQOL的特定因素。本研究采用横断面设计，纳入了56名年龄和糖化血红蛋白（HbA1c）匹配的T1D和T2D患者（年龄68.9±7.8岁；55%患有T2D）。我们使用了几份经过验证的问卷（简短健康调查问卷36项版（SF-36）和欧洲五维健康量表/视觉模拟量表（VAS））来研究HRQOL领域与糖尿病类型、血糖控制、并发症和合并症之间的关系。T1D与更好的自我报告的总体健康状况相关（通过SF-36总体健康领域评估（ = 0.048）和欧洲五维健康量表VAS评估（ = 0.002）），而在其他SF-36领域、自我报告的糖尿病困扰、焦虑或抑郁方面未发现显著差异。大多数HRQOL领域与HbA1c或糖尿病并发症的存在无关。无论糖尿病类型如何，BMI较高的患者HRQOL下降最为显著。所获得的HRQOL数据可用于临床环境中，为针对特定患者亚组的循证患者教育提供依据，也可用于国家医疗政策，例如旨在减轻肥胖的干预措施。
